During the past decade, Grand Hopital de Charleroi conducted 99 clinical trials. In the 10-year time frame, 99 clinical trials started and 32 clinical trials were completed, i.e. on average, 32.3% percent of trials that started reached the finish line to date. In the past 5 years, 45 clinical trials started and 24 clinical trials were completed. i.e. 53.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Grand Hopital de Charleroi" #1 sponsor was "Celgene" with 10 trials, followed by "Cliniques universitaires Saint-Luc- Université Catholique de Louvain" with 10 trials sponsored, "Jules Bordet Institute" with 9 trials sponsored, "The Lymphoma Academic Research Organisation" with 9 trials sponsored and "Pfizer" with 9 trials sponsored. Other sponsors include 85 different institutions and companies that sponsored additional 66 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Grand Hopital de Charleroi" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 6 trials as a collaborator, "Genmab" with 5 trials as a collaborator, "Hoffmann-La Roche" with 4 trials as a collaborator, "Belgian Gynaecological Oncology Group" with 3 trials as a collaborator and "Eli Lilly and Company" with 3 trials as a collaborator. Other collaborators include 83 different institutions and companies that were collaborators in the rest 84 trials.

According to Clinical.Site data, the most researched conditions in "Grand Hopital de Charleroi" are "Breast Cancer" (6 trials), "Myelodysplastic Syndromes" (5 trials), "Heart Failure" (4 trials), "Leukemia, Myeloid, Acute" (4 trials) and "Solid Tumors" (4 trials). Many other conditions were trialed in "Grand Hopital de Charleroi" in a lesser frequency.

Most popular intervention types in "Grand Hopital de Charleroi" are "Drug" (115 trials), "Other" (14 trials), "Procedure" (8 trials), "Biological" (6 trials) and "Diagnostic Test" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (20 trials), "Carboplatin" (7 trials), "Rituximab" (7 trials), "Gemcitabine" (6 trials) and "Irinotecan" (5 trials). Other intervention names were less common.

The vast majority of trials in "Grand Hopital de Charleroi" are 119 trials for "All" genders and 16 trials for "Female" genders.

Currently, there are NaN active trials in "Grand Hopital de Charleroi". undefined are not yet recruiting, 31 are recruiting, 23 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 55 completed trials in Grand Hopital de Charleroi, 1 suspended trials, and 15 terminated clinical trials to date.

Out of the total trials that were conducted in Grand Hopital de Charleroi, 18 "Phase 1" clinical trials were conducted, 49 "Phase 2" clinical trials and 56 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 10 trials that are defined as “Not Applicable".

Grand Hopital de Charleroi has several departments that took part in Clinical trials: "Department of Pneumology Hôpital Saint-Joseph" - 7 trials, "Grand Hôpital de Charleroi Oncologie-Hématologie" - 5 trials